Infliximab in the treatment of rheumatoid arthritis

Jenny Augustsson*, Thorunn Jonsdottir, Lars Klareskog, Ronald F. van Vollenhoven

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Rheumatoid arthritis is a chronic inflammatory systemic autoimmune disorder characterized by symmetric inflammation of synovial joints, leading to progressive erosion of cartilage and bone. Tumor necrosis factor-α antagonists have set a new therapeutic standard for rheumatoid arthritis. Tumor necrosis factor-α blocking agents, including infliximab, etanercept and adalimumab, have demonstrated substantial improvement in signs and symptoms, disability and quality of life, while significantly inhibiting joint damage in early and long-standing rheumatoid arthritis. The focus of this article will be the role of infliximab in the treatment of rheumatoid arthritis.

Original languageEnglish
Pages (from-to)19-33
Number of pages15
JournalAging Health
Volume2
Issue number1
DOIs
Publication statusPublished - Feb 2006

Other keywords

  • Arthritis
  • Autoimmune
  • Elderly
  • Inflammation
  • Infliximab
  • Rheumatoid
  • Tumor necrosis factor

Fingerprint

Dive into the research topics of 'Infliximab in the treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this